What Is Enterostatin? Definition and What Research Reports

Enterostatin is a short peptide — a pentapeptide, meaning it is five amino acids long — that is released when the pancreatic protein precursor procolipase is cleaved during fat digestion in the small intestine. Because it appears as a by-product of the same process that allows pancreatic lipase to work on dietary fat, enterostatin has been described in the physiology literature as a candidate signal linking fat digestion to the control of fat intake, a framing set out in a 2004 review of enterostatin and its target mechanisms during the regulation of fat intake (PMID 15621068). It is a naturally occurring endogenous fragment rather than a synthetic analogue designed in a laboratory, although synthetic versions of the sequence have been used in experiments.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health or treatment question. Nothing here describes how any substance should be used, and enterostatin is not an approved medicine — the published work summarised below is preclinical laboratory and animal research.

Where the molecule comes from

Colipase is the co-factor that pancreatic lipase requires in order to break down triglycerides at the fat–water interface in the gut lumen. Colipase is secreted by the pancreas in an inactive form, procolipase, and activation involves removal of an N-terminal pentapeptide. That removed pentapeptide is enterostatin. In other words, enterostatin is not secreted as a stand-alone hormone from a dedicated gland; it is generated stoichiometrically as part of the machinery of fat digestion, which is one reason researchers examined whether its release could act as a feedback signal proportional to the amount of fat being digested (PMID 15621068).

Molecule class at a glance

How the term is used in peptide research

In the peptide and ingestive-behaviour literature, "enterostatin" usually refers to the synthetic or purified pentapeptide used as an experimental tool rather than to a therapy. Researchers administered it in animal models by peripheral routes and also directly into the brain — including intracerebroventricular injection and injection into discrete nuclei such as the amygdala — in order to map which circuits respond to it (PMID 15312796). The term also appears in mechanistic papers as shorthand for a signalling probe: studies used it to interrogate downstream pathways such as melanocortin receptor signalling (PMID 17113194) and intracellular cyclic AMP and ERK cascades (PMID 19059445).

Readers encountering the word in an abstract will most often find it in one of three contexts: (1) feeding studies measuring macronutrient selection, especially fat versus carbohydrate; (2) neuroanatomical studies mapping activation markers in the hypothalamus and related regions; and (3) metabolic or cell-biology studies examining pancreatic, mitochondrial or vascular endpoints.

What the published literature reports

Fat intake and the melanocortin system

A 2007 study in Peptides reported that the inhibition of dietary fat intake associated with enterostatin was modulated through the melanocortin system, linking the peptide's feeding effect to a well-characterised hypothalamic pathway rather than to a simple aversive or gastrointestinal response (PMID 17113194). A related 2009 report described that enterostatin affected cyclic AMP and ERK signalling pathways to regulate expression of agouti-related protein (AgRP), an orexigenic peptide within that same melanocortin circuitry (PMID 19059445). Together these papers positioned enterostatin as an upstream input to melanocortin signalling in the published model.

Brain circuits activated after administration

A 2004 Brain Research study reported that enterostatin delivered into the amygdala induced c-Fos expression — a standard marker of neuronal activation — in hypothalamic regions that innervate the paraventricular nucleus (PVN) (PMID 15312796). That finding is frequently cited as anatomical support for the idea that the peptide engages distributed forebrain and hypothalamic circuitry involved in ingestive behaviour rather than acting at a single site.

Central versus peripheral administration

Route mattered in the experimental literature. A 2006 study in the American Journal of Physiology compared central and peripheral injection of enterostatin and reported different metabolic responses depending on where the peptide was delivered (PMID 16339388). This is a recurring caution in reviews of the peptide: results obtained after direct brain administration in rodents are not interchangeable with results obtained after systemic administration.

Pancreatic and endocrine endpoints

Beyond feeding behaviour, a 2005 study reported that enterostatin decreased postprandial pancreatic uncoupling protein 2 (UCP2) mRNA levels and increased plasma insulin and amylin in the animal model examined (PMID 15713687). Those endpoints connect the peptide to islet function and to mitochondrial uncoupling proteins, which is why enterostatin sometimes appears in metabolic-signalling papers unrelated to appetite as such.

Non-feeding laboratory findings

The peptide has also been examined outside ingestive physiology. A 2008 paper in the International Journal of Obesity reported inhibition of angiogenesis by enterostatin and discussed a possible role of phosphorylated AMPK and vascular endothelial growth factor A (VEGF-A) in that effect (PMID 18301390). This line of work is separate from the feeding literature and is generally described as exploratory.

Safety and Adverse Events: What Studies Report

The verified papers summarised on this page were mechanistic and preclinical, and their reported endpoints were feeding behaviour, brain activation markers, pancreatic gene expression, circulating hormones and vascular signalling rather than formal safety or tolerability outcomes (PMID 15621068, PMID 15713687). Because of that, this entry does not list an adverse-event profile: no human safety data set is described in the sources cited here, and the absence of reported harms in animal mechanism papers is not evidence of safety in people. Questions about risk belong with a licensed clinician.

How the term relates to neighbouring concepts

• Procolipase / colipase — the parent protein and the fat-digestion co-factor whose activation releases the pentapeptide (PMID 15621068).
• Melanocortin system — the hypothalamic pathway through which the fat-intake effect was reported to be modulated (PMID 17113194).
• AgRP — an orexigenic peptide whose expression was reported to be regulated via cyclic AMP and ERK signalling in enterostatin experiments (PMID 19059445).
• UCP2, insulin and amylin — pancreatic and endocrine endpoints measured in the postprandial study (PMID 15713687).
• AMPK and VEGF-A — signalling molecules discussed in the angiogenesis report (PMID 18301390).

Limits of the current record

The enterostatin literature is dominated by rodent and cell-based work, and much of the mechanistic detail in the papers above came from animal models in which the peptide was delivered directly to brain regions. The 2004 review itself framed the target mechanisms as an open question rather than a settled account (PMID 15621068), and the route-dependence reported in 2006 underlines how sensitive the observed metabolic responses were to experimental design (PMID 16339388). Readers comparing sources should note publication year, species, route of administration and measured endpoint before assuming that two papers describe the same phenomenon.

References

• Enterostatin and its target mechanisms during regulation of fat intake (Physiology & Behavior, 2004)
• Enterostatin inhibition of angiogenesis: possible role of pAMPK and vascular endothelial growth factor A (VEGF-A) (International Journal of Obesity, 2008)
• Enterostatin inhibition of dietary fat intake is modulated through the melanocortin system (Peptides, 2007)
• Different metabolic responses to central and peripheral injection of enterostatin (American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 2006)
• Enterostatin decreases postprandial pancreatic UCP2 mRNA levels and increases plasma insulin and amylin (American Journal of Physiology: Endocrinology and Metabolism, 2005)
• Amygdala enterostatin induces c-Fos expression in regions of hypothalamus that innervate the PVN (Brain Research, 2004)
• Enterostatin affects cyclic AMP and ERK signaling pathways to regulate Agouti-related protein (AgRP) expression (Peptides, 2009)